A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients

详细信息    查看全文

• 作者：Tyler Albright ; PharmD¹ ; Akram Al-Makki ; MD ; FACP ; FASN² ; Rabih Kalakeche ; MD² ; Brian Shepler ; PharmD³ ; ^{sheplerb@purdue.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：anemia ; chronic kidney disease ; ferric pyrophosphate citrate ; hemodialysis ; hemoglobin ; soluble ferric pyrophosphate
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：38
• 期：10
• 页码：2318-2323
• 全文大小：148 K

文摘

The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.

Methods

A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.

Findings

Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.

Implications

This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.